Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 VGXI Opens Flex-Scale Plant for GMP RNA and DNA Mfg. | Contract Pharma
Breaking News

VGXI Opens Flex-Scale Plant for GMP RNA and DNA Mfg.

U.S. Congressman Kevin Brady visited Texas-based CMO VGXI to celebrate the occasion

VGXI, a plasmid DNA contract manufacturing organization, unveiled the grand opening of a facility expansion which includes flexible scale plasmid DNA manufacturing space as well as purpose-built GMP production areas for RNA synthesis.
 
Increasing the company’s footprint by 17% and cGMP manufacturing space by over 70%, this expansion was initiated in anticipation of the recently finalized license and partnership with Houston Methodist Research Institute (HMRI). Under the partnership, technology transfer for clinical grade RNA manufacturing capabilities is already underway from HMRI, providing an ideal complement to VGXI’s existing DNA production services.
 
The ribbon cutting ceremony was attended by U.S. Congressman Kevin Brady as well representatives of the Texas biotechnology community, including BioHouston chief executive officer, Ann Tanabe. During the ceremony Congressman Brady presented VGXI’s president and chief executive officer, Young Park with a commendation on behalf of the U.S. House of Representatives for the company’s continued contributions to the biotechnology industry and local community.
 
In response to the growing success and worldwide demand for gene-based medicines, VGXI has continued to improve and broaden their services with three facility expansions in just the past 4 years. According to Mr. Park, “The current expansion is just one part of the company’s overall plan to keep pace with industry. We are already evaluating locations for VGXI’s next phase facility for commercial DNA and RNA production.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters